September 9, 2020 Clinical Research/Diagn. Licensing, IP, and Legal

Roche expands its multiple sclerosis portfolio with investigational BTK inhibitor fenebrutinib and initiates novel clinical trials for OCREVUS (ocrelizumab)

Phase III clinical trial programme initiated for investigational medicine fenebrutinib, designed to be a highly selective and reversible Bruton’s tyrosine kinase (BTK) inhibitor, in relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS) Phase IIIb clinical trial programme of higher-dose OCREVUS (ocrelizumab) to evaluate impact on reducing disability progression in RMS and PPMS OCREVUS CHIMES... Read more

September 3, 2020 Licensing, IP, and Legal Product Launch

Roche to present new data in multiple sclerosis and neuromyelitis optica spectrum disorder at MSVirtual2020

New data further reinforce OCREVUS (ocrelizumab) as a highly effective treatment option offering a favourable and consistent benefit:risk profile, with high treatment persistence and adherence Initiation of Phase IIIb OCREVUS higher dose clinical trial programme and Phase IV study evaluating OCREVUS in minority populations Initiation of Phase III clinical trial programme for fenebrutinib, an investigational... Read more

August 28, 2020 Chromatography Lab Top-10 Licensing, IP, and Legal Molecular Spectroscopy

Shimadzu and HORIBA to Collaborate on Development and Sales of LC-Raman Analytical and Measuring InstrumentsTowards the Commercialization of Analytical and Measuring Instruments that Combine a High-Performance Liquid Chromatograph and a Raman Spectrometer

08/28/2020 |   Press Release Towards the Commercialization of Analytical and Measuring Instruments that Combine a High-Performance Liquid Chromatograph and a Raman Spectrometer On August 3rd, Shimadzu Corporation (President & CEO: Teruhisa Ueda, hereinafter Shimadzu) and HORIBA, Ltd. (President & COO: Masayuki Adachi, hereinafter HORIBA) concluded a basic agreement to commence collaboration on the development and sales of... Read more

August 27, 2020 Licensing, IP, and Legal Liq. Handling & Robotics

Brooks to Participate in the Citi's 2020 Global Technology Virtual Conference

CHELMSFORD, Mass., Aug. 27, 2020 /PRNewswire/ — Brooks Automation, Inc. (Nasdaq:BRKS) announced today that company management will participate in Citi’s 2020 Global Technology Virtual Conference on Wednesday, September 9, 2020 which includes a 45-minute webcast beginning at 9:50 a.m. ET.  The live webcast can be accessed through the Brooks investor relations website at www.brooks.investorroom.com/events. A replay... Read more

August 25, 2020 Clinical Research/Diagn. Licensing, IP, and Legal Life Science Tools

Fluidigm Granted FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19

Easy-to-Administer Saliva Test for COVID-19 Available for Immediate Shipment Extraction-Free, Real-Time PCR Workflow with Capacity of up to 6,000 Tests per Day per System Demonstrated 100 Percent Agreement with Authorized Nasopharyngeal Assays SOUTH SAN FRANCISCO, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) — Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight,... Read more

August 19, 2020 Clinical Research/Diagn. Licensing, IP, and Legal Life Science Tools

Zymo Research Granted CE IVD Mark for Quick SARS-CoV-2 rRT-PCR Kit

IRVINE, Calif., (Aug. 19, 2020) — Zymo Research announced that it was recently granted the CE IVD Mark for its Quick SARS-CoV-2 rRT-PCR Kit. To obtain this certification the product had to comply with the Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on in vitro diagnostic medical devices. The Quick SARS-CoV-2 rRT-PCR Kit is... Read more

August 10, 2020 Acad, Gov/Utilities Licensing, IP, and Legal

FDA approves Roche’s Evrysdi (risdiplam) for treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older

Basel, 10 August 2020 In two clinical trials, Evrysdi improved motor function in people living with SMA over a broad spectrum of ages and levels of disease severity, including Types 1, 2, and 3 SMA Evrysdi helped infants survive without permanent ventilation and achieve the ability to sit without support, a key motor milestone not... Read more

August 6, 2020 Bio/Pharma/CRO Licensing, IP, and Legal

Roche provides update on Phase III study of Tecentriq in combination with paclitaxel for people with metastatic triple-negative breast cancer

Basel, 06 August 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpassion131 study, evaluating Tecentriq® (atezolizumab) in combination with paclitaxel (chemotherapy), in comparison to placebo plus paclitaxel, did not meet statistical significance on its primary endpoint of progression-free survival (PFS) for the initial (first-line) treatment of people with metastatic... Read more

August 4, 2020 Licensing, IP, and Legal

The United States Court of Appeals for the Federal Circuit Affirms that 10x Genomics Willfully Infringed Bio-Rad U.S. Patent and Upholds Lower Court’s Award of Damages

HERCULES, Calif. –Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced that the The United States Court of Appeals for the Federal Circuit today affirmed that 10x Genomics willfully infringed U.S. Patent 8,889,083, exclusively licensed to Bio-Rad from the University of Chicago. The Appeals Court upheld... Read more

August 4, 2020 Licensing, IP, and Legal Liq. Handling & Robotics Microscopy

Brooks to Participate in the Needham Virtual SemiCap and EDA Investor Conference

CHELMSFORD, Mass., Aug. 4, 2020 /PRNewswire/ — Brooks Automation, Inc. (Nasdaq:BRKS) announced today that company management will participate in the Needham Virtual SemiCap and Electronic Design Automation Conference on Thursday, August 13, 2020 at 9:30 a.m. ET.  The 40-minute session will be webcast live via the Brooks investor relations website at www.brooks.investorroom.com/events. About Brooks AutomationBrooks... Read more